Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS111283)
National Institute of General Medical Sciences (4U54GM104944-04, P20GM1033408)
American Heart Association (19TPA34860008, 1656450)
Received: 12 August 2020
Accepted: 3 November 2020
First Online: 12 November 2020
Ethics approval and consent to participate
: This study was approved as exempt by the local governing IACUC review board.
: BAM is a full-time employee of Alcyone Therapeutics and has received grant support from Minnetronix Neuro, Biogen, Genentech, Voyager Therapeutics, and Alcyone Therapeutics. BAM is a scientific advisory board member for Alcyone Lifesciences, International Society for Hydrocephalus and CSF Disorders, and the Chiari and Syringomyelia Foundation and has served as a consultant to Flux Neuroscience, Genentech, Roche, Biogen, Praxis Medicines, InviCRO, SwanBio Therapeutics, Cerebral Therapeutics, Minnetronix Neuro, and CereVasc.